JBJunyoung Byeon

Junyoung Byeon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junyoung Byeon has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Dong-Keon Lee

    Division of Research Program, Scripps Korea Antibody Institute, Chuncheon 24341, Gangwon-do, Republic of Korea

    2 shared publications
  • Minsik Park

    Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon, Republic of Korea

    2 shared publications
  • Young-Guen Kwon

    Advanced Institute of Technology, Curacle Co., Ltd., Seoul, Republic of Korea

    2 shared publications
  • Young-Myeong Kim

    Department of Molecular and Cellular Biochemistry, School of Medicine, Kangwon National University, Chuncheon, Republic of Korea

    2 shared publications
  • Chanin Park

    Division of Life Sciences, Division of Applied Life Science, Gyeongsang National University, Jinju, Republic of Korea

    1 shared publication
  • Gihwan Lee

    Division of Life Sciences, Division of Applied Life Science, Gyeongsang National University, Jinju, Republic of Korea

    1 shared publication

Latest Publications

  • Open Access

    The REDD1–NF-κB–miRNAs–eNOS/SIRT1 axis mediates obesity-induced endothelial cell senescence and hypertension

    by Yoon Kyung Choi, Dong-Keon Lee, Minsik Park, Junyoung Byeon, Woo-Young Nam, Thuy Linh Lai, Kyu Nam Kim, Okhwa Kim, Sungwoo Ryoo, Jeong-Hyung Lee, et al.

    Vascular dysfunction, including endothelial cell (EC) senescence and hypertension, is a hallmark of metabolic syndrome, yet its underlying mechanisms remain unclear. Here, we show that metabolic stress upregulates regulated in development and DNA damage response 1 (REDD1), driving vascular dysfunction. Overexpression of REDD1, but not the REDD1KK219/220AA mutant, which cannot activate atypical NF-κB, promotes EC senescence and hypertension through NF-κB-dependent induction of miR-155-5p and miR-214-3p. These miRNAs suppress endothelial nitric oxide synthase (eNOS) and SIRT1 expression in human and mouse ECs. In obese male mice, REDD1 and miR-214-3p are upregulated, whereas eNOS and SIRT1 are downregulated, contributing to EC senescence, renal dysfunction, and hypertension. This phenotype is alleviated in mice lacking Redd1, EC-specific Redd1, or miR-214-3p, and in mice expressing Redd1KK219/220AA, but only partially by IKKβ inhibition. These findings identify a REDD1–atypical NF-κB–miRNAs–eNOS/SIRT1 axis as a critical mediator of obesity-induced vascular dysfunction and a promising therapeutic target.


  • Open Access

    REDD1 promotes obesity-induced metabolic dysfunction via atypical NF-κB activation

    by Dong-Keon Lee, Taesam Kim, Junyoung Byeon, Minsik Park, Suji Kim, Joohwan Kim, Seunghwan Choi, Gihwan Lee, Chanin Park, Keun Woo Lee, et al.

    Regulated in development and DNA damage response 1 (REDD1) expression is upregulated in response to metabolic imbalance and obesity. However, its role in obesity-associated complications is unclear. Here, we demonstrate that the REDD1–NF-κB axis is crucial for metabolic inflammation and dysregulation. Mice lacking Redd1 in the whole body or adipocytes exhibited restrained diet-induced obesity, inflammation, insulin resistance, and hepatic steatosis. Myeloid Redd1-deficient mice showed similar results, without restrained obesity and hepatic steatosis. Redd1-deficient adipose-derived stem cells lost their potential to differentiate into adipocytes; however, REDD1 overexpression stimulated preadipocyte differentiation and proinflammatory cytokine expression through atypical IKK-independent NF-κB activation by sequestering IκBα from the NF-κB/IκBα complex. REDD1 with mutated Lys219/220Ala, key amino acid residues for IκBα binding, could not stimulate NF-κB activation, adipogenesis, and inflammation in vitro and prevented obesity-related phenotypes in knock-in mice. The REDD1-atypical NF-κB activation axis is a therapeutic target for obesity, meta-inflammation, and metabolic complications.